Loading...
XSHE000989
Market cap863mUSD
Jan 10, Last price  
7.48CNY
1D
-1.06%
1Q
6.55%
Jan 2017
-65.55%
Name

Jiuzhitang Co Ltd

Chart & Performance

D1W1MN
XSHE:000989 chart
P/E
21.29
P/S
2.17
EPS
0.35
Div Yield, %
5.41%
Shrs. gr., 5y
-0.16%
Rev. gr., 5y
-1.58%
Revenues
2.92b
-3.76%
1,022,387,1891,050,301,465946,530,7891,024,108,0141,101,092,5951,109,212,0051,122,389,7521,149,805,5631,042,414,9781,211,844,1401,405,350,432871,512,6802,673,798,0433,797,212,5933,162,109,0033,183,694,7893,559,540,9633,784,155,2363,033,265,8592,919,332,628
Net income
297m
-16.92%
105,786,06023,569,09640,306,819127,814,993199,893,946148,315,410162,691,134201,779,214111,562,163224,830,507245,740,572471,031,522651,809,785712,254,464336,479,563192,146,815272,309,874270,696,505357,985,434297,411,075
CFO
121m
-75.68%
100,537,22558,075,253135,961,08381,447,770131,212,474220,921,862185,789,943139,721,17387,775,86528,454,244118,592,670339,026,372612,378,390151,996,083425,861,442851,290,910609,555,035365,912,082499,132,759121,397,805
Dividend
May 28, 20240.4 CNY/sh
Earnings
May 16, 2025

Profile

Jiuzhitang Co., Ltd. provides traditional Chinese, chemical, biological, and health medicine products in China. The company offers shuxuetong injections, Angong Niuhuang Wan, Danxi granules, and Gastrodia Uncaria for cardiovascular and cerebrovascular disease; Guizhi Fuling pills, Buxue Shengru granules, and hemostasis and analgesia products for gynecological disease; Schicon for respiratory disease; and Jiaqi Ganzian granules, Jianwei Yuyang tablets, Jienchang Ning, and Chidan yellowing products for digestive disease. It also provides non-prescription drugs for treating nourishing QI and blood, cardiovascular and cerebrovascular, urinary system, pediatric, gynecological, skeletal muscle, respiratory, dermatology, nervous system, ENT, digestive system, and tumor diseases. Jiuzhitang Co., Ltd. was founded in 1999 and is headquartered in Beijing, China.
URL
https://www.hnjzt.com/
IPO date
Jun 28, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,919,333
-3.76%
3,033,266
-19.84%
Cost of revenue
2,333,316
2,586,442
Unusual Expense (Income)
NOPBT
586,017
446,824
NOPBT Margin
20.07%
14.73%
Operating Taxes
54,787
101,065
Tax Rate
9.35%
22.62%
NOPAT
531,229
345,758
Net income
297,411
-16.92%
357,985
32.25%
Dividends
(342,377)
(342,377)
Dividend yield
3.95%
4.54%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
114,852
77,424
Long-term debt
17,984
18,347
Deferred revenue
40,314
40,028
Other long-term liabilities
2,748
6,189
Net debt
(1,457,786)
(1,639,677)
Cash flow
Cash from operating activities
121,398
499,133
CAPEX
(72,844)
Cash from investing activities
(301,842)
83,967
Cash from financing activities
(236,349)
FCF
361,989
621,809
Balance
Cash
903,916
1,089,345
Long term investments
686,706
646,102
Excess cash
1,444,656
1,583,784
Stockholders' equity
2,398,811
2,463,192
Invested Capital
2,669,567
2,468,477
ROIC
20.68%
12.97%
ROCE
14.10%
10.92%
EV
Common stock shares outstanding
855,859
855,942
Price
10.12
14.87%
8.81
-18.88%
Market cap
8,661,295
14.86%
7,540,849
-18.76%
EV
7,198,554
5,901,172
EBITDA
713,256
594,607
EV/EBITDA
10.09
9.92
Interest
3,612
3,786
Interest/NOPBT
0.62%
0.85%